Latest Ribavirin Stories
The drug telaprevir (Incivek) provides a dramatic improvement in the treatment of the most common form of hepatitis C infection.
PRINCETON, N.J., June 22, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces that the United States Patent and Trademark Office has issued U.S. patent 7,964,580 ("the '580 patent") titled "Nucleoside Phosphoramidate Prodrugs".
PRINCETON, N.J., June 8, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today the addition of three treatment cohorts to the ELECTRON trial of PSI-7977, a nucleotide analog polymerase inhibitor, for the treatment of chronic hepatitis C (HCV).
Global branding firm names newly approved INCIVEK. (PRWEB) June 03, 2011 Addison Whitney is pleased to announce the FDA approval of INCIVEKâ„¢ (telaprevir) from Vertex Pharmaceuticals Incorporated. INCIVEK is a prescription medication used with peginterferon alfa and ribavirin.
SAN DIEGO, June 1, 2011 /PRNewswire/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) today announced issuance of the U.S. patent covering setrobuvir (ANA598), the Company's Direct-Acting Antiviral (DAA) in Phase IIb development for chronic hepatitis C virus infection (HCV). U.S. Patent No.
PRINCETON, N.J., May 26, 2011 /PRNewswire/ -- Pharmasset, Inc.
Vertex Pharmaceuticals Inc's highly anticipated hepatitis C drug has finally won US approval, which will usher in a new marketing battle with a rival medicine from Merck & Co.
SILVER SPRING, Md., May 23, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Incivek (telaprevir) to treat certain adults with chronic hepatitis C infection.
HUDDINGE, Sweden, May 20, 2011 /PRNewswire/ -- - All TMC435 Patient Subgroups Achieved Substantially Higher SVR4 Rates (Undetectable Virus 4 Weeks After End of Treatment) Compared to pegylated-interferon and ribavirin Alone - TMC435 was Safe and Well Tolerated at All Doses and Treatment Durations Medivir AB (OMX: MVIR), the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announced results from the ASPIRE phase 2b study that...
WHITEHOUSE STATION, N.J., May 14, 2011 /PRNewswire/ -- Merck (NYSE: MRK) (known as MSD outside the United States and Canada) announced today that the U.S.
Lassa fever, first described in 1969 in Lassa, is an acute viral hemorrhagic fever. Clinical cases were known a decade before this but were not associated with this viral pathogen. It is endemic in West African countries and causes approximately 5,000 deaths. The Natal Multimammate Mouse is the primary animal host. The rodent is a source of protein but the virus is usually transmitted by the contact with the feces and urine of animals accessing grain stores in residences. The lassa virus...